Division of Clinical Pharmacy, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.
Department of Medicine, Hadassah University Hospital, Jerusalem, Israel.
Age Ageing. 2018 Mar 1;47(2):201-208. doi: 10.1093/ageing/afx167.
zolpidem, zopiclone, eszopiclone and zaleplon, also known as 'Z-drugs', are commonly used as alternatives to benzodiazepines (BZDs) to treat insomnia. Z-drugs are often perceived as safer than BZDs. We conducted a systematic review and meta-analysis evaluating the association between Z-drugs and fracutres, falls and injuries.
a systematic review was performed using MEDLINE, EMBASE and ClinicalTials.gov. Pooled effect-sizes were calculated comparing Z-drugs users with non-users, using fixed and random-effect models with corresponding 95% confidence of intervals (CI).
we identified 14 eligible studies reporting on the association between Z-drugs and outcomes of interest. Z-Drugs were associated with a statistically significant increased risk for fractures, with evidence of considerable heterogeneity (OR = 1.63; 95% CI: 1.42-1.87; I2 = 90%; n = 830,877). Likewise, there was a trend suggesting a 2-fold increase in the odds for falls, however, this result was not statistically significant and there was evidence of considerable heterogeneity (OR = 2.40; 95% CI: 0.92-6.27; I2 = 95%; n = 19,505). In an analysis assessing the risk for injuries following exposure to zolpidem we found a statistically significant increased risk of injuries, with no evidence of heterogeneity (OR = 2.05; CI 95%: 1.95-2.15; I2 = 0; n = 160,502). Results were similar in sensitivity analyses, including analyses restricted to studies of high-quality, studies with control groups suffering from insomnia, and with specific Z-drugs.
our results indicate that Z-drugs are associated with an increased risk for fractures, and suggest a possible increased risk for falls and injuries as well. However, studies included were observational and susceptible to confounding. Physicians should consider these potential risks before prescribing these medications in older adults.
唑吡坦、佐匹克隆、右佐匹克隆和扎来普隆,也被称为“Z 类药物”,通常被用作苯二氮䓬类药物(BZDs)的替代品,用于治疗失眠。Z 类药物通常被认为比 BZDs 更安全。我们进行了一项系统评价和荟萃分析,评估 Z 类药物与骨折、跌倒和损伤之间的关联。
使用 MEDLINE、EMBASE 和 ClinicalTrials.gov 进行系统评价。使用固定效应模型和随机效应模型,计算比较 Z 类药物使用者与非使用者的汇总效应大小,并计算相应的 95%置信区间(CI)。
我们确定了 14 项符合纳入标准的研究,报告了 Z 类药物与研究结果之间的关联。Z 类药物与骨折风险显著增加相关,存在相当大的异质性(OR = 1.63;95%CI:1.42-1.87;I2 = 90%;n = 830,877)。同样,有证据表明跌倒的几率增加了两倍,但这一结果没有统计学意义,且存在相当大的异质性(OR = 2.40;95%CI:0.92-6.27;I2 = 95%;n = 19,505)。在评估暴露于唑吡坦后受伤风险的分析中,我们发现受伤的风险显著增加,且无异质性证据(OR = 2.05;CI 95%:1.95-2.15;I2 = 0;n = 160,502)。敏感性分析结果相似,包括仅限于高质量研究、使用失眠对照组的研究以及特定 Z 类药物的研究。
我们的结果表明,Z 类药物与骨折风险增加相关,并提示可能增加跌倒和损伤的风险。然而,纳入的研究是观察性的,容易受到混杂因素的影响。在为老年人开这些药物之前,医生应考虑这些潜在风险。